Valuation — not yet established
No valuation for RevBio is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($45.8M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for RevBio
Create free account
No card required
Funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Apr 2023 | Early Stage VC | $10.0M | ▮ | ▮ |
| Jun 2021 | Early Stage VC | $9.0M | ▮ | ▮ |
How RevBio's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For RevBio, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has RevBio raised?
- RevBio has raised $45.8M in total funding across 2 recorded rounds.
- When did RevBio last raise?
- RevBio last raised in Apr 2023 (Early Stage VC), raising $10.0M.